ROQ — Roquefort Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- £2.20m
- £2.40m
- 14
- 49
- 19
- 14
Annual cashflow statement for Roquefort Therapeutics, fiscal year end - December 31st, GBP millions except per share, conversion factor applied.
R2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final |
| Net Income/Starting Line | -0.996 | -1.63 | -1.93 | -1.21 |
| Depreciation | ||||
| Amortisation | ||||
| Non-Cash Items | 0.365 | 0.017 | 0.223 | 0.416 |
| Other Non-Cash Items | ||||
| Changes in Working Capital | 0.114 | 0.039 | -0.028 | 0.009 |
| Change in Accounts Receivable | ||||
| Change in Inventories | ||||
| Change in Accounts Payable | ||||
| Change in Payable / Accrued Expenses | ||||
| Cash from Operating Activities | -0.517 | -1.58 | -1.73 | -0.784 |
| Capital Expenditures | — | — | -0.054 | — |
| Purchase of Fixed Assets | ||||
| Other Investing Cash Flow Items | -0.606 | -0.103 | 0.001 | 0 |
| Acquisition of Business | ||||
| Other Investing Cash Flow | ||||
| Cash from Investing Activities | -0.606 | -0.103 | -0.053 | 0 |
| Financing Cash Flow Items | -0.159 | -0.019 | -0 | — |
| Other Financing Cash Flow | ||||
| Net Issuance / Retirement of Stock | ||||
| Net Issuance / Retirement of Debt | ||||
| Cash from Financing Activities | 2.02 | 3.1 | -0 | 0.585 |
| Foreign Exchange Effects | ||||
| Beginning Cash Balance | ||||
| Ending Cash Balance | ||||
| Net Change in Cash | 0.9 | 1.42 | -1.79 | -0.2 |